Skip to main
PYPD
PYPD logo

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd is a late-stage biopharmaceutical company specializing in PLEX-based therapies aimed at preventing surgical site infections (SSI), with its lead candidate D-PLEX100 showing promising efficacy-risk profiles in a Phase 3 clinical study involving colorectal cancer patients. Recently, the company announced a new financing agreement, facilitating the immediate exercise of outstanding warrants, which is expected to raise approximately $26.7 million, enhancing its financial resources for upcoming regulatory interactions. This capital influx positions PolyPid to potentially file a New Drug Application (NDA) for D-PLEX100 by the first half of 2026, further strengthening its pipeline and operational outlook.

Bears say

PolyPid Ltd faces significant risks related to the efficacy of its clinical-stage product candidates, as failure to deliver statistically significant results in studies could greatly diminish their potential value. Additionally, even successful clinical outcomes may not guarantee regulatory approval from domestic or foreign agencies, further jeopardizing the company's valuation. Compounded by complex patent procedures, potential revenue erosion has been anticipated starting in 2036, adding to the negative outlook on PolyPid’s stock.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Nov 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.